Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
Back to dashboard
Company Information
About this company
Key people
Kevin Schuyler
Lead Independent Chairman of the Board
Cary J. Claiborne
President, Chief Executive Officer, Director
Vinay Shah
Chief Financial Officer
Matthew Davidson
President, Chief Executive Officer, Director
Wendy B. Young
Director
J. Kermit Anderson
Independent Director
Robertson H. Gilliland
Independent Director
Click to see more
Key facts
- Shares in issue2.63m
- EPICADIL
- ISINUS00688A3041
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$16.32m
- Employees5
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.